Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
July 23 2019 - 1:00AM
Sanofi signs strategic deal for exclusive US over-the-counter
rights to Tamiflu® in Flu Care
Sanofi signs strategic deal for
exclusive US over-the-counter rights to
Tamiflu® in Flu
Care
PARIS – July 23, 2019 – Sanofi
signed an agreement with Roche for the exclusive over-the-counter
(OTC) rights to Tamiflu® for the prevention and treatment of
influenza or flu in the US. Under the terms of the agreement,
Sanofi will be responsible for leading FDA negotiations for the OTC
switch and subsequent exclusive marketing, scientific engagement
and distribution of Tamiflu OTC in the US. Tamiflu is currently
sold in the US by Genentech, a member of the Roche Group, for
prescription use.
“This is a strategic and important transaction
for us as we strive to continually bring innovations to the
market,” says Alan Main, Executive Vice President, Consumer
Healthcare, Sanofi. “The US market is the largest OTC market in the
world and a successful switch of Tamiflu to OTC would support our
global cough and cold strategy by expanding into flu with a
sustainable point of difference in the market. Tamiflu will offer a
significant public health benefit once switched by providing
increased access to a safe and efficacious treatment for the
prevention and treatment of flu. People would be able to either
reduce their chances of getting the flu or, at the first signals,
appropriately treat as early as possible during the crucial first
48 hours without having to wait for a doctor’s appointment.”
Flu is a condition for which there is no
effective OTC anti-viral treatment. Currently consumers are only
able to treat flu symptoms with the available OTC products. Early
treatment will help prevent unnecessary spread of the disease.
According to the Centers for Disease Control and Prevention (CDC),
over 31 million people in the US suffer from the flu in the US each
year, but only about 7 million were treated with an effective
product like Tamiflu in 2017.
Under the agreement, in addition to leading the
FDA negotiations, Sanofi will be responsible for leading the
clinical program and funding all studies needed to support the OTC
switch in the US in consultation with leading experts in the field.
Roche will continue to market Tamiflu in the rest of the world.
Sanofi will retain the rights to first negotiations for switch
rights in other selected markets.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe. Sanofi, Empowering Life |
Media Relations Contact Chrystel Baude Tel:
+33 (0)1 53 77 46 46 mr@sanofi.com |
Investor Relations
Contact George Grofik Tel: +33 (0)1 53 77 45 45
ir@sanofi.com |
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
“expects”, “anticipates”, “believes”, “intends”, “estimates”,
“plans” and similar expressions. Although Sanofi’s management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi’s ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2018. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements. |